Zetomipzomib (KZR-616), A First-in-Class, Selective Immunoproteasome Inhibitor, Achieved Clinically Meaningful Renal Responses in Refractory or Hard-To-Treat Patients With Lupus Nephritis: Completed Phase 2 MISSION Study Results
.
American Society of Nephrology’s Kidney Week 2022 (ASN 2022).
